DRUG TEXT
ZWR
^PS(51.7,0)="DRUG TEXT^51.7^31^30"
^PS(51.7,1,0)="HYPERTENSION-VA/DOD"
^PS(51.7,1,2,0)="^^1^1^3000208^^^^"
^PS(51.7,1,2,1,0)="Refer to VA/DoD Hypertension treatment guidelines"
^PS(51.7,2,0)="SPINAL CORD,NEUROLOGY,REHAB"
^PS(51.7,2,2,0)="^^1^1^2990909^^"
^PS(51.7,2,2,1,0)="RESTRICTED TO SPINAL CORD INJURY,NEUROLOGY,AND REHABILITATION"
^PS(51.7,3,0)="HIV/AIDS"
^PS(51.7,3,2,0)="^^1^1^2990922^^"
^PS(51.7,3,2,1,0)="Refer to HIV/AIDS TAG treatment guidelines"
^PS(51.7,4,0)="DIABETES^2991126"
^PS(51.7,4,2,0)="^^1^1^2990922^^^^"
^PS(51.7,4,2,1,0)="Refer to PBM/MAP and PBM/TAG Diabetes treatment guidelines"
^PS(51.7,5,0)="CHF"
^PS(51.7,5,2,0)="^^1^1^2991028^^^^"
^PS(51.7,5,2,1,0)="Refer to PBM/MAP CHF treatment guidelines"
^PS(51.7,6,0)="GERD"
^PS(51.7,6,2,0)="^^1^1^2990922^^^"
^PS(51.7,6,2,1,0)="Refer to PBM/MAP GERD treatment guidelines"
^PS(51.7,7,0)="PUD"
^PS(51.7,7,2,0)="^^1^1^2990922^^"
^PS(51.7,7,2,1,0)="Refer to PBM/MAP PUD treatment guidelines"
^PS(51.7,8,0)="COPD"
^PS(51.7,8,2,0)="^^1^1^2990922^^"
^PS(51.7,8,2,1,0)="Refer to VA/DoD COPD treatment guidelines"
^PS(51.7,9,0)="DIHYDROPYRIDINE CALCIUM ANTAGONISTS"
^PS(51.7,9,2,0)="^^2^2^2990909^^"
^PS(51.7,9,2,1,0)="Refer to PBM/MAP criteria for use of long-acting dihydropyridine calcium "
^PS(51.7,9,2,2,0)="antagonists"
^PS(51.7,10,0)="HYPERLIPIDEMIA"
^PS(51.7,10,2,0)="^^1^1^2990922^^^"
^PS(51.7,10,2,1,0)="Refer to VA/DoD Hyperlipidemia treatment guidelines"
^PS(51.7,11,0)="NEUROLOGY"
^PS(51.7,11,2,0)="^^1^1^2990922^^^"
^PS(51.7,11,2,1,0)="RESTRICTED TO NEUROLOGY"
^PS(51.7,12,0)="SMOKING CESSATION"
^PS(51.7,12,2,0)="^^1^1^2990909^^"
^PS(51.7,12,2,1,0)="RESTRICTED TO SMOKING CESSATION PROGRAMS"
^PS(51.7,14,0)="BPH"
^PS(51.7,14,2,0)="^^1^1^2990926^^^^"
^PS(51.7,14,2,1,0)="Refer to PBM/MAP benign Prostatic Hyperplasia treatment guidelines"
^PS(51.7,15,0)="ATORVASTATIN"
^PS(51.7,15,2,0)="^^1^1^2990909^^"
^PS(51.7,15,2,1,0)="Refer to PBM/MAP criteria for use of atorvastatin"
^PS(51.7,16,0)="TROVAFLOXACIN"
^PS(51.7,16,2,0)="^^1^1^2990909^^^"
^PS(51.7,16,2,1,0)="Refer to PBM/MAP criteria for use of trovafloxacin"
^PS(51.7,17,0)="THIAZOLIDINEDIONES"
^PS(51.7,17,2,0)="^^1^1^2990909^^"
^PS(51.7,17,2,1,0)="Refer to PBM/MAP criteria for use of thiazolidinediones"
^PS(51.7,18,0)="LANSOPRAZOLE"
^PS(51.7,18,2,0)="^^1^1^2990922^^^"
^PS(51.7,18,2,1,0)="Refer to PBM/MAP dosing guidelines for lansoprazole"
^PS(51.7,19,0)="CELECOXIB"
^PS(51.7,19,2,0)="^^1^1^2990909^^^"
^PS(51.7,19,2,1,0)="Refer to PBM/MAP criteria for use of celecoxib"
^PS(51.7,20,0)="BECALPERMIN"
^PS(51.7,20,2,0)="^^1^1^2990909^^^"
^PS(51.7,20,2,1,0)="Refer to PBM/MAP criteria for use of becalpermin"
^PS(51.7,21,0)="DEPRESSION^2991126"
^PS(51.7,21,2,0)="^^1^1^2990922^^^"
^PS(51.7,21,2,1,0)="Refer to PBM/MAP Depression treatment guidelines"
^PS(51.7,22,0)="ALBUMIN"
^PS(51.7,22,2,0)="^^1^1^2990922^^^"
^PS(51.7,22,2,1,0)="Refer to PBM/MAP guidelines for use of albumin"
^PS(51.7,23,0)="HYPERTENSION/CHF-VA/DOD-PBM/MAP"
^PS(51.7,23,2,0)="^^1^1^2990925^^^^"
^PS(51.7,23,2,1,0)="Refer to VA/DoD Hypertension treatment and PBM/MAP CHF treatment guidelines"
^PS(51.7,24,0)="HYPERTENSION/CHF/DIABETES"
^PS(51.7,24,2,0)="^^2^2^2990925^^^^"
^PS(51.7,24,2,1,0)="Refer to PBM/MAP Hypertension treatment and CHF treatment guidelines and "
^PS(51.7,24,2,2,0)="PBM/TAG Diabetes treatment guidelines"
^PS(51.7,25,0)="HYPERTENSION-PBM/MAP"
^PS(51.7,25,2,0)="^^1^1^2990925^^^"
^PS(51.7,25,2,1,0)="Refer to PBM/MAP Hypertension treatment guidelines"
^PS(51.7,26,0)="REVIEW"
^PS(51.7,26,2,0)="^^1^1^2991105^^"
^PS(51.7,26,2,1,0)="Class review in progress"
^PS(51.7,27,0)="HYPERTENSION/CHF-PBM"
^PS(51.7,27,2,0)="^^1^1^2990925^^^"
^PS(51.7,27,2,1,0)="Refer to PBM/MAP Hypertension treatment and CHF treatment guidelines"
^PS(51.7,28,0)="ALZHEIMER'S"
^PS(51.7,28,2,0)="^^2^2^2990926^"
^PS(51.7,28,2,1,0)="Refer to Pharmacologic Management of Cognitive Changes in Alzheimer's "
^PS(51.7,28,2,2,0)="Disease"
^PS(51.7,29,0)="BPH/HYPERTENSION"
^PS(51.7,29,2,0)="^^2^2^2990926^"
^PS(51.7,29,2,1,0)="Refer to PBM/MAP benign Prostatic Hyperplasia treatment and Hypertension"
^PS(51.7,29,2,2,0)="treatment guidelines"
^PS(51.7,30,0)="NON-FORMULARY ALERT"
^PS(51.7,30,2,0)="^^2^2^3110529^"
^PS(51.7,30,2,1,0)="THIS IS A NON-FORMULARY ITEM. PLEASE USE A SUITABLE ALTERNATIVE OR SUBMIT "
^PS(51.7,30,2,2,0)="A NON-FORMULARY REQUEST!"
^PS(51.7,31,0)="FORMULARY"
^PS(51.7,31,2,0)="^^1^1^3110530^"
^PS(51.7,31,2,1,0)="THIS IS A FORMULARY PREFERRED ITEM"
^PS(51.7,"B","ALBUMIN",22)=""
^PS(51.7,"B","ALZHEIMER'S",28)=""
^PS(51.7,"B","ATORVASTATIN",15)=""
^PS(51.7,"B","BECALPERMIN",20)=""
^PS(51.7,"B","BPH",14)=""
^PS(51.7,"B","BPH/HYPERTENSION",29)=""
^PS(51.7,"B","CELECOXIB",19)=""
^PS(51.7,"B","CHF",5)=""
^PS(51.7,"B","COPD",8)=""
^PS(51.7,"B","DEPRESSION",21)=""
^PS(51.7,"B","DIABETES",4)=""
^PS(51.7,"B","DIHYDROPYRIDINE CALCIUM ANTAGO",9)=""
^PS(51.7,"B","FORMULARY",31)=""
^PS(51.7,"B","GERD",6)=""
^PS(51.7,"B","HIV/AIDS",3)=""
^PS(51.7,"B","HYPERLIPIDEMIA",10)=""
^PS(51.7,"B","HYPERTENSION-PBM/MAP",25)=""
^PS(51.7,"B","HYPERTENSION-VA/DOD",1)=""
^PS(51.7,"B","HYPERTENSION/CHF-PBM",27)=""
^PS(51.7,"B","HYPERTENSION/CHF-VA/DOD-PBM/MA",23)=""
^PS(51.7,"B","HYPERTENSION/CHF/DIABETES",24)=""
^PS(51.7,"B","LANSOPRAZOLE",18)=""
^PS(51.7,"B","NEUROLOGY",11)=""
^PS(51.7,"B","NON-FORMULARY ALERT",30)=""
^PS(51.7,"B","PUD",7)=""
^PS(51.7,"B","REVIEW",26)=""
^PS(51.7,"B","SMOKING CESSATION",12)=""
^PS(51.7,"B","SPINAL CORD,NEUROLOGY,REHAB",2)=""
^PS(51.7,"B","THIAZOLIDINEDIONES",17)=""
^PS(51.7,"B","TROVAFLOXACIN",16)=""
